Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling

Despite their ability to reduce fracture-risk and increase Bone Mineral Density (BMD) in osteoporotic women, bisphosphonates are reported to reduce formation of new bone. Reduced bone formation has been suggested to lead to accumulation of microfractures and contribute to rare side effects in cortical bone such as atypical femur fractures. However, most studies are limited to trabecular bone. In this study, the cortical bone remodeling in human iliac bone specimens of 65 non-treated and 24 alendronate-treated osteoporotic women was investigated using a new histomorphometric classification of intracortical pores. The study showed that only 12.4 +/- 11% of the cortical pore area reflected quiescent pores/osteons in alendronate-treated patients versus 8.5 +/- 5% in placebo, highlighting that new cortical remodeling events remain to be activated. The percent and size of eroded pores (events in resorption-reversal phase) remained unchanged, but their contribution to total pore area was 1.4-fold higher in alendronate versus placebo treated patients (66 +/- 22% vs 48 +/- 22%, p < 0.001). On the other hand, the mixed eroded-formative pores (events with mixed resorption-reversal-formation phases) was 2-fold lower in alendronate versus placebo treated patients (19 +/- 14% vs 39 +/- 23% of total pore area, p < 0.001), and formative pores (event in formation phase) was 2.2-fold lower in alendronate versus placebo treated patients (2.1 +/- 2.4% vs 4.6 +/- 3.6%, p < 0.01), and their contribution to total pore area was 2.4-fold lower (1.3 +/- 2.1% vs 3.1 +/- 4.4%, p < 0.05). Importantly, these differences between alendronate and placebo treated patients were significant in patients after 3 years of treatment, not after 2 years of treatment. Collectively, the results support that cortical remodeling events activated during alendronate treatment has a prolonged reversal-resorption phase with a delayed transition to formation, becoming increasingly evident after 3-years of treatment. A potential contributor to atypical femur fractures associated with long-term bisphosphonate treatment.

Automated summary

The study found that patients treated with bisphosphonates had fewer quiescent pores/osteons compared to placebo-treated patients, indicating that new cortical remodeling events need to be activated. Additionally, the contribution of eroded pores in the resorption-reversal phase was higher in bisphosphonate-treated patients, while the contribution of mixed eroded-formative pores and formative pores was lower in these patients compared to placebo.